Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 16

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 16
---
 more complete description of the treatment of Aptorum securities in the Merger, please see the sections titled “The Merger Agreement — Treatment of Aptorum Ordinary Shares”. Immediately after the Merger, Aptorum shareholders as of immediately prior to the Merger are expected to own approximately 30% of the outstanding shares of Aptorum following the Merger (the “Combined Company”), while DiamiR stockholders are expected to own approximately 70% of the outstanding shares of the Combined Company. Q:Why are the two companies proposing to merge? A:Aptorum and DiamiR believe that combining the two companies will create synergies, innovation and operational efficiencies that can create long term value for stockholders. Following the Merger, the Combined Company will utilize DiamiR’s biomarker panels in various clinical studies, including through collaborations with academic institutions and clinical centers in the US and other countries through its CEO’s extensive global medical network, expanding therapeutic focus and geographical outreach for the Combined Company. For a more complete description of the reasons for the Merger, please see the sections titled “The Merger — Aptorum’s Reasons for the Merger” and “— DiamiR’s Reasons for the Merger”. Q:What will happen to Aptorum if, for any reason, the Merger with DiamiR does not close? A:Aptorum has invested significant time and incurred, and expects to continue to incur, significant expenses related to the proposed Merger with DiamiR. In the event the Merger does not close, Aptorum will have a limited ability to continue its current operations indefinitely. Although the Aptorum board of directors may elect, among other things, to attempt to complete another strategic transaction if the Merger with DiamiR does not close, it may not be able to find a third party willing to provide equivalent or more attractive consideration than the consideration to be provided by each party in the Merger. In such circumstances, Aptorum’s board of directors may elect to, among other things, divest all or a portion of Aptorum’s business, and in such case, the consideration that Aptorum shareholders receive may be less attractive than the consideration to be received by Aptorum pursuant to the Merger Agreement. Q:Why is Aptorum proposing the Domestication? A:The Aptorum Board believes that there are significant advantages to the Combined Company that will arise as a result of a change of Aptorum’s domicile to the State of Delaware, including: (i) the prominence, predictability and flexibility of the DG